Revlimid Generic Revs Up Dr Reddy’s To Record Gains, There’s More To Come

Generic Revlimid US sales propel Dr Reddy’s to a record fiscal second quarter, with the management indicating that “meaningful” contributions are likely in the coming months too. The Indian firm also expects to deploy its healthy cash flows for deal-making, aided by tempered valuations in some segments amid geopolitical and economic turbulence.

Revlimid Generic Propels Sharp Earnings Delta For Dr Reddy's • Source: Shutterstock

Generic Revlimid (lenalidomide) brought extended festive season cheer to Dr. Reddy's Laboratories Ltd.'s investors after the Indian firm’s earnings rose sharply in the fiscal second quarter buoyed by US sales of the cancer therapy.

While Dr Reddy’s declined to specify the actual contribution of lenalidomide to its topline - analysts estimate it could be...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip